TY  - JOUR
AU  - Tristan-Manzano, Maria
AU  - Maldonado-Perez, Noelia
AU  - Justicia-Lirio, Pedro
AU  - Muñoz, Pilar
AU  - Cortijo-Gutierrez, Marina
AU  - Pavlovic, Kristina
AU  - Jimenez-Moreno, Rosario
AU  - Nogueras, Sonia
AU  - Carmona, M Dolores
AU  - Sanchez-Hernandez, Sabina
AU  - Aguilar-Gonzalez, Araceli
AU  - Castella, Maria
AU  - Juan, Manel
AU  - Marañon, Concepcion
AU  - Marchal, Juan Antonio
AU  - Benabdellah, Karim
AU  - Herrera, Concha
AU  - Martin, Francisco
PY  - 2022
DO  - 10.1016/j.omto.2022.05.003
SN  - 2372-7705
UR  - http://hdl.handle.net/10668/22464
T2  - Molecular therapy oncolytics
AB  - Anti-CD19 chimeric antigen receptor (CAR)-T cells have achieved impressive outcomes for the treatment of relapsed and refractory B-lineage neoplasms. However, important limitations still remain due to severe adverse events (i.e., cytokine release...
LA  - en
PB  - Cell Press
KW  - CAR-T
KW  - T cells phenotype
KW  - TCR-like expression
KW  - WAS gene promoter
KW  - Exhaustion
KW  - Lentiviral vectors
KW  - Leukemia
KW  - Lymphoma
KW  - Physiological expression
KW  - Tonic signaling
TI  - Physiological lentiviral vectors for the generation of improved CAR-T cells.
TY  - research article
VL  - 25
ER  -